Jul 2026
A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy
Dacarbazine-based chemotherapy retains modest activity in selected patients with advanced melanoma in the immunotherapy-refractory setting, and further multicenter studies are required to define predictive biomarkers and optimize patient selection.
Maleeha Anwar, G. Meléndez-Torres, R. Frazer
· Anticancer Research · 0 citations